EuBiologics Co., Ltd. (KOSDAQ:206650)
South Korea · Delayed Price · Currency is KRW 9,080.00
-70.00 (-0.77%)
Aug 11, 2026, 2:24 PM KST
EuBiologics Revenue
In the year 2024, EuBiologics had annual revenue of 96.04B KRW with 38.45% growth. EuBiologics had revenue of 26.89B in the quarter ending December 31, 2023, with 54.38% growth.
Revenue
96.04B
Revenue Growth
+62.39%
P/S Ratio
3.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
336.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 96.04B | 26.67B | 38.45% |
| Dec 31, 2023 | 69.37B | 13.90B | 25.06% |
| Dec 31, 2022 | 55.47B | 16.08B | 40.83% |
| Dec 31, 2021 | 39.38B | 10.90B | 38.24% |
| Dec 31, 2020 | 28.49B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| JW Holdings | 973.26B |
| Huons Global | 845.30B |
| Dong-A ST | 830.27B |
| Suheung | 743.02B |
| Huons | 616.80B |
| Samjin Pharmaceuticals | 274.03B |
| Shinpoong Pharmaceutical Co.,Ltd | 233.80B |
| Bukwang Pharmaceutical | 200.68B |